Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | -126.32% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.59 | N/A | -126.32% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach regarding future performance. They emphasized the importance of ongoing clinical development.
Management did not provide specific details on revenue expectations.
The focus remains on advancing clinical programs.
This earnings report indicates that IDEAYA Biosciences I is facing challenges, particularly in terms of EPS performance. The stock reacted negatively, declining by 1.71%, likely due to the disappointing EPS figure and lack of revenue data. Investors may be concerned about the company's future financial outlook without clear guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARRIOTT INTL INC NE Class A
Aug 10, 2020